The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

Robert Malone, who believes the U.S. government has “reality-bending information-control capabilities,” will guide the future ...

Amidst an ongoing outbreak of a deadly bird flu virus in livestock, the US Department of Agriculture is doing more to prevent ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

Several states have effectively declared war on medical progress. Lawmakers in Iowa, Idaho, Texas, and Kentucky have introduced bills that would ban or restrict vaccines that use messenger RNA, or ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

The negative sentiment towards the S&P 500 Health Care Index Sector (XLV) softened in May as average short interest dipped to ...

The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.